Publications by authors named "Karen Apelskog-Torres"
Article Synopsis
- Selegiline (L-deprenyl) is primarily used to treat Parkinson's disease as a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at standard doses, but higher doses show potential antidepressant effects by possibly inhibiting MAO-A as well.
- Zydis selegiline (Zelapar) is a fast-dissolving version that allows for better absorption, leading to increased plasma levels and fewer metabolite effects compared to regular selegiline; however, its selectivity for MAO-B may diminish at higher dosages.
- A study found that a 10 mg daily dose of Zydis selegiline significantly inhibited MAO-A in healthy men, providing the first direct
Reversible inhibitors of monoamine oxidase-A (RIMA) inhibit the breakdown of three major neurotransmitters, serotonin, norepinephrine and dopamine, offering a multi-neurotransmitter strategy for the treatment of depression. CX157 (3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide) is a RIMA, which is currently in development for the treatment of major depressive disorder. We examined the degree and reversibility of the inhibition of brain monoamine oxidase-A (MAO-A) and plasma CX157 levels at different times after oral dosing to establish a dosing paradigm for future clinical efficacy studies, and to determine whether plasma CX157 levels reflect the degree of brain MAO-A inhibition.
View Article and Find Full Text PDFContext: Modafinil, a wake-promoting drug used to treat narcolepsy, is increasingly being used as a cognitive enhancer. Although initially launched as distinct from stimulants that increase extracellular dopamine by targeting dopamine transporters, recent preclinical studies suggest otherwise.
Objective: To measure the acute effects of modafinil at doses used therapeutically (200 mg and 400 mg given orally) on extracellular dopamine and on dopamine transporters in the male human brain.